When the Miracle Feels Like a Migraine

The pharmaceutical industry is a paradox.

On one hand, it’s the reason antibiotics exist, vaccines stop pandemics, and millions of people live longer, healthier lives. On the other hand, it’s the reason your neighbour is crowdfunding for cancer treatment while the CEO of a drug company is buying his third yacht.

We trust the science. We don’t always trust the system. And that tension is the pill nobody wants to swallow.

Pharma loves to tell the story of itself as the great innovator. The adverts are full of white coats, microscopes, and smiling children who’ve been “given a future.” And yes, let’s be fair: the breakthroughs are astonishing. HIV treatments, cancer immunotherapies, insulin, and vaccines. Lives saved, lives extended.

But the halo of innovation hides the shadows:

• Overprescribing: when “normal life” becomes a diagnosis. Feeling sad? Pill. Can’t sleep? Pill. Child fidgeting? Pill.
• Marketing muscle: billions spent not on research, but on persuading doctors and patients to prefer their pill over another.
• Access gaps: the miracle drug exists, but only if you can afford it.

Innovation is real. But so is inequity.

The emotional terrain is messy.

• Gratitude: for the antibiotics that stop infections, the inhalers that keep lungs open, the painkillers that make life bearable.
• Distrust: of pricing strategies that make insulin unaffordable in some countries, of lobbying that shapes policy behind closed doors, of scandals where safety data was massaged.
• Exhaustion: from the sense that health has become a marketplace, where care is packaged, branded, and sold like shampoo.

It’s not that people don’t value medicines. They just don’t want to feel like customers in a shop when they’re at their most vulnerable.

Here’s where it gets cheeky. Pills have become cultural accessories.

• The “I can’t function without my morning vitamins” crowd.
• The “I’ve got a pill for that” jokers at dinner parties.
• The influencer‑adjacent supplement stacks that look more like altar offerings than healthcare.

It’s not that conditions aren’t real; they are. But the cultural drift is toward medicalising everything, smoothing out every bump in the human experience. And that’s profitable.

The cheeky truth? Sometimes pharma doesn’t just sell cures. It sells identities.

And here’s where it keeps getting backed up: the system itself.

• Regulation vs. speed: patients want faster access, regulators want safety. Cue delays, frustration, and accusations of “red tape.”
• Profit vs. equity: shareholders want returns, patients want affordability. Cue headlines about billion-dollar profits alongside people crowdfunding for treatment.
• Science vs. marketing: researchers want evidence, marketers want stories. Cue glossy adverts that oversimplify complex realities.

The backlog isn’t just in warehouses or supply chains. It’s in the clash of values.

Bring up pharma at a dinner party and watch the room split.

• One person will say: “But without them, we’d all be dead by 40.”
• Another will mutter: “Yeah, but they’re basically legalised cartels.”
• Someone else will joke about side effects: “May cause dizziness, nausea, existential dread…”

And everyone’s right, in their own way. That’s the tension. We can’t live without it, but we’re not sure we can live comfortably with it either.

Here’s the uncomfortable truth: health has been reframed as a commodity. Pills are products. Patients are customers. Doctors are sometimes sales reps in disguise.

And once health is a marketplace, the logic shifts. Care is no longer the measure of success. Profit is. That’s why the same pill can cost pennies in one country and hundreds in another. That’s why “rare diseases” are sometimes ignored by not enough customers.

What if we stopped treating pharma as a business empire and started treating it as part of a commons?

• Medicines as shared resources, not luxury goods.
• Research as a collective endeavour, not a proprietary secret.
• Care as the measure of success, not quarterly profit.

This isn’t utopian fluff. It’s already happening in pockets: open‑source drug development, patient-led research, and community pharmacies pushing for cultural competence.

So where does that leave us? Somewhere between awe and suspicion. Between gratitude for the science and frustration at the system. Between the miracle of a pill and the migraine of its price tag.

The pharmaceutical industry is both a miracle and a machine. It saves lives, but it also sells them back at a price. The tension is not going away, because it’s baked into the structure: care and commerce, side by side.

The invitation is not to throw the pills away, nor to swallow them blindly. It’s to keep asking: what would it look like if medicines were treated not as commodities, but as companions? Not as products, but as promises?

Because health is not just a market. It’s a human right. And until we treat it that way, the tension will keep getting backed up.

“Exciting news: Spiralmore, the cross-disciplinary project hub, is evolving! A new version is coming soon to help you combine accessibility with sustainability, science, and reflective learning. Stay tuned for updates.”